Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

DBV Technologies

DB:DBVA
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DBVA
DB
€389M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • DBV Technologies has significant price volatility in the past 3 months.
DBVA Share Price and Events
7 Day Returns
-0.6%
DB:DBVA
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-54.8%
DB:DBVA
-13.2%
DE Biotechs
-20.9%
DE Market
DBVA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
DBV Technologies (DBVA) -0.6% -56% -67.3% -54.8% -89.5% -86.4%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • DBVA underperformed the Biotechs industry which returned -13.2% over the past year.
  • DBVA underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
DBVA
Industry
5yr Volatility vs Market
Related Companies

DBVA Value

 Is DBV Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of DBV Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for DBV Technologies.

DB:DBVA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:DBVA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.1%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 33%) (6.21%))
1.159
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.16
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.159 * 6.07%)
6.65%

Discounted Cash Flow Calculation for DB:DBVA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for DBV Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:DBVA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.65%)
2020 -193.05 Analyst x6 -181.02
2021 -144.97 Analyst x6 -127.47
2022 6.29 Analyst x1 5.18
2023 86.23 Analyst x1 66.66
2024 112.28 Analyst x1 81.39
2025 131.08 Est @ 16.75% 89.10
2026 146.29 Est @ 11.61% 93.25
2027 158.01 Est @ 8.01% 94.44
2028 166.68 Est @ 5.49% 93.42
2029 172.89 Est @ 3.72% 90.86
Present value of next 10 years cash flows €305.00
DB:DBVA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €172.89 × (1 + -0.39%) ÷ (6.65% – -0.39%)
€2,447.96
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €2,447.96 ÷ (1 + 6.65%)10
€1,286.46
DB:DBVA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €305.00 + €1,286.46
€1,591.46
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €1,591.46 / 54.86
€29.01
DB:DBVA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:DBVA represents 0.46512x of ENXTPA:DBV
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.46512x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 29.01 x 0.46512
€13.49
Value per share (EUR) From above. €13.49
Current discount Discount to share price of €3.30
= -1 x (€3.30 - €13.49) / €13.49
75.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price DBV Technologies is available for.
Intrinsic value
>50%
Share price is €3.3 vs Future cash flow value of €13.49
Current Discount Checks
For DBV Technologies to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • DBV Technologies's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • DBV Technologies's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for DBV Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are DBV Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:DBVA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-4.15
ENXTPA:DBV Share Price ** ENXTPA (2020-04-03) in EUR €7.1
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of DBV Technologies.

DB:DBVA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:DBV Share Price ÷ EPS (both in EUR)

= 7.1 ÷ -4.15

-1.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DBV Technologies is loss making, we can't compare its value to the Europe Biotechs industry average.
  • DBV Technologies is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does DBV Technologies's expected growth come at a high price?
Raw Data
DB:DBVA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.71x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
53.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for DBV Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on DBV Technologies's assets?
Raw Data
DB:DBVA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €3.73
ENXTPA:DBV Share Price * ENXTPA (2020-04-03) in EUR €7.1
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:DBVA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:DBV Share Price ÷ Book Value per Share (both in EUR)

= 7.1 ÷ 3.73

1.9x

* Primary Listing of DBV Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DBV Technologies is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess DBV Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. DBV Technologies has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

DBVA Future Performance

 How is DBV Technologies expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
53.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is DBV Technologies expected to grow at an attractive rate?
  • DBV Technologies's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • DBV Technologies's earnings growth is expected to exceed the Germany market average.
  • DBV Technologies's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:DBVA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:DBVA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 53.8%
DB:DBVA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 50.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:DBVA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:DBVA Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 563 166 264 2
2023-12-31 388 62 157 2
2022-12-31 170 -45 25 3
2021-12-31 72 -136 -146 5
2020-12-31 14 -166 -182 5
2020-04-05
DB:DBVA Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 13 -129 -154
2019-09-30 11 -139 -162
2019-06-30 11 -149 -174
2019-03-31 11 -143 -170
2018-12-31 11 -137 -166
2018-09-30 10 -136 -153
2018-06-30 9 -124 -147
2018-03-31 9 -119 -147
2017-12-31 10 -114 -148
2017-09-30 10 -100 -143
2017-06-30 9 -85 -138
2017-03-31 9 -72 -126

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • DBV Technologies's earnings are expected to grow significantly at over 20% yearly.
  • DBV Technologies's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:DBVA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from DBV Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DBVA Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 -3.03 -1.71 -4.10 4.00
2020-12-31 -3.58 -3.03 -4.12 4.00
2020-04-05
DB:DBVA Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -4.15
2019-09-30 -4.89
2019-06-30 -5.51
2019-03-31 -5.62
2018-12-31 -5.74
2018-09-30 -5.56
2018-06-30 -5.60
2018-03-31 -5.78
2017-12-31 -5.97
2017-09-30 -5.78
2017-06-30 -5.59
2017-03-31 -5.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if DBV Technologies will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess DBV Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
DBV Technologies has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

DBVA Past Performance

  How has DBV Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare DBV Technologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • DBV Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare DBV Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare DBV Technologies's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
DBV Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from DBV Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DBVA Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 13.14 -153.59 63.34 101.50
2019-09-30 11.42 -161.70 71.04 102.71
2019-06-30 11.32 -173.81 78.95 107.39
2019-03-31 11.25 -169.94 77.62 105.93
2018-12-31 11.19 -166.08 76.30 104.47
2018-09-30 9.65 -153.22 66.07 100.78
2018-06-30 9.05 -147.23 58.32 100.67
2018-03-31 9.32 -147.46 56.00 101.94
2017-12-31 9.60 -147.69 53.69 103.21
2017-09-30 9.55 -142.66 53.45 100.53
2017-06-30 9.49 -137.63 53.21 95.19
2017-03-31 8.51 -126.08 50.71 85.39
2016-12-31 7.53 -114.53 48.20 76.93
2016-09-30 7.48 -97.09 41.55 64.22
2016-06-30 7.43 -79.64 34.90 52.84
2016-03-31 6.93 -63.26 27.08 43.68
2015-12-31 6.17 -44.67 18.45 33.06
2015-09-30 5.72 -35.70 14.23 27.86
2015-06-30 5.27 -26.72 9.70 22.70
2015-03-31 4.94 -24.93 8.02 22.43
2014-12-31 4.76 -24.01 8.39 20.87
2014-09-30 4.96 -23.59 7.87 21.07
2014-06-30 5.15 -23.17 8.03 20.73
2014-03-31 4.44 -20.56 7.97 17.55
2013-12-31 3.83 -19.31 6.31 17.37
2013-09-30 3.31 -17.35 6.17 15.04
2013-06-30 2.80 -15.39 5.77 12.98

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if DBV Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if DBV Technologies has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if DBV Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess DBV Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
DBV Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

DBVA Health

 How is DBV Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up DBV Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • DBV Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • DBV Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of DBV Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 140.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from DBV Technologies Company Filings, last reported 3 months ago.

DB:DBVA Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 171.56 1.30 172.03
2019-09-30 85.84 1.44 73.01
2019-06-30 116.33 1.58 107.27
2019-03-31 116.33 1.58 107.27
2018-12-31 121.29 2.48 122.77
2018-09-30
2018-06-30 204.92 3.60 202.25
2018-03-31 204.92 3.60 202.25
2017-12-31 129.92 4.15 137.88
2017-09-30 129.92 4.15 137.88
2017-06-30 191.68 4.47 198.69
2017-03-31 191.68 4.47 198.69
2016-12-31 242.85 4.64 256.47
2016-09-30 242.85 4.64 256.47
2016-06-30 290.49 4.82 288.76
2016-03-31 290.49 4.82 288.76
2015-12-31 322.08 4.84 323.38
2015-09-30 322.08 4.84 323.38
2015-06-30 105.64 4.87 104.53
2015-03-31 111.60 4.92 110.31
2014-12-31 115.45 4.13 114.58
2014-09-30 115.45 4.13 114.58
2014-06-30 31.55 1.56 29.06
2014-03-31 40.39 1.44 39.40
2013-12-31 40.40 1.44 39.40
2013-09-30 40.39 1.44 39.40
2013-06-30 33.47 1.54 32.27
  • DBV Technologies's level of debt (0.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (3.6% vs 0.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • DBV Technologies has sufficient cash runway for 1.3 years based on current free cash flow.
  • DBV Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 35.3% each year.
X
Financial health checks
We assess DBV Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. DBV Technologies has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

DBVA Dividends

 What is DBV Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from DBV Technologies dividends. Estimated to be 0% next year.
If you bought €2,000 of DBV Technologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate DBV Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate DBV Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:DBVA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:DBVA Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as DBV Technologies has not reported any payouts.
  • Unable to verify if DBV Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of DBV Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as DBV Technologies has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of DBV Technologies's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess DBV Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can DBV Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. DBV Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

DBVA Management

 What is the CEO of DBV Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Daniel Tassé
COMPENSATION €2,772,270
AGE 59
TENURE AS CEO 1.4 years
CEO Bio

Mr. Daniel Tassé has been the Chief Executive Officer at DBV Technologies S.A. since November 29, 2018 and has been its Director since March 4, 2019. He served as the Chairman and Chief Executive Officer of Alcresta Therapeutics, Inc. Mr. Tassé serves as Senior Advisor at Bridge Growth Partners, LLC. An accomplished healthcare executive, he has built and led businesses with global footprints in the fields of bio-pharmaceuticals, medical devices, diagnostics and health services. Prior to the acquisition of Ikaria by Mallinckrodt in April 2015, Mr. Tassé was President and Chief Executive Officer and Chairman of the Board of Ikaria and served as Interim Chief Executive Officer and President of Bellerophon Therapeutics, Inc. from February 2014 to June 2014. He has more than 35 years of biopharmaceutical leadership experience. He served as the Chairman of the Board of Ikaria, Inc. since October 2009 until 2015 and its Chief Executive Officer and President since January 2008 until April 2015. Mr. Tassé served as the General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International, Inc. He served as President and Regional Director for Australasia at GlaxoSmithKline from 2001 to 2004. He held management positions at Upjohn. He had been Director at Bellerophon Therapeutics, Inc. from February 2014 until May 14, 2019. Mr. Tassé has been an Independent Director of Regenxbio Inc. since August 2016. Mr. Tassé has been an Independent Non-Executive Director of Indivior PLC since November 04, 2014 and has been its Senior Independent Director since September 30, 2016. He was an Independent Director of HLS Therapeutics Inc until March 21, 2019. He serves as a Member of Technology Advisory Board and Member of Strategic Advisory Board at Bridge Growth Partners, LLC. He has been Director of BioQ Pharma Incorporated since July 2015. He served as a Director and a Member of Health Section Governing Board at Biotechnology Innovation Organization from July 2011 to June 2015. He served as a Director of Ikaria Holdings, Inc. since January 2008 until April 2015. From 2011 to 2015, he served as a Board Director of PhRMA. He serves as the Chairman of the Foundation on National Critical Care Policy. He serves at the Sheikh Zayed Institute Business Advisory Council in DC. He is a board director of the Roundtable on Critical Care Policy. He was a Member of the Healthcare Leadership Council from 2010 to June 2015. Mr. Tassé holds a B.Sc. in Biochemistry from the University of Montreal and is fluent in both French and English.

CEO Compensation
  • Daniel's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Daniel's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the DBV Technologies management team in years:

3.9
Average Tenure
59
Average Age
  • The tenure for the DBV Technologies management team is about average.
Management Team

Daniel Tassé

TITLE
CEO & Director
COMPENSATION
€3M
AGE
59
TENURE
1.4 yrs

Pierre-Henri Benhamou

TITLE
Co-Founder & Member of Scientific Advisory Board
COMPENSATION
€26K
AGE
64
TENURE
18.3 yrs

Ramzi Benamar

TITLE
Chief Financial Officer
AGE
46
TENURE
0.3 yrs

Pascal Wotling

TITLE
Chief Technical Operations Officer

Hugh Sampson

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board
AGE
70
TENURE
4.4 yrs

Sara Sherman

TITLE
Senior Director of Investor Relations & Strategy

Joe Becker

TITLE
Vice President of Global Corporate Communications

Caroline Daniere

TITLE
Chief Human Resources Officer
AGE
45
TENURE
0.6 yrs

Wence Agbotounou

TITLE
Chief Clinical Trial Officer & Senior VP
TENURE
3.9 yrs

Lucie Mondoulet

TITLE
Senior VP & Deputy CSO
TENURE
3.9 yrs
Board of Directors Tenure

Average tenure and age of the DBV Technologies board of directors in years:

1.1
Average Tenure
64
Average Age
  • The average tenure for the DBV Technologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Michel de Rosen

TITLE
Independent Non-Executive Chairman
COMPENSATION
€142K
AGE
68
TENURE
1.1 yrs

Daniel Tassé

TITLE
CEO & Director
COMPENSATION
€3M
AGE
59
TENURE
1.1 yrs

Pierre-Henri Benhamou

TITLE
Co-Founder & Member of Scientific Advisory Board
COMPENSATION
€26K
AGE
64
TENURE
1.1 yrs

Hugh Sampson

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board
AGE
70

Torbjørn Bjerke

TITLE
Independent Director
COMPENSATION
€87K
AGE
57
TENURE
14.3 yrs

Christophe Dupont

TITLE
Chairman of the Scientific Advisory Board

Claire Giraut

TITLE
Independent Director
COMPENSATION
€90K
AGE
63
TENURE
3.8 yrs

Paul-Henri Lambert

TITLE
Member of the Scientific Advisory Board
AGE
80

Gideon Lack

TITLE
Member of the Scientific Advisory Board

Robert Zeiger

TITLE
Member of the Scientific Advisory Board
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess DBV Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. DBV Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

DBVA News

Simply Wall St News

DBVA Company Info

Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn’s disease, hemophilia A, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Details
Name: DBV Technologies S.A.
DBVA
Exchange: DB
Founded: 2002
€389,257,497
54,863,636
Website: http://www.dbv-technologies.com
Address: DBV Technologies S.A.
177-181 avenue Pierre Brossolette,
Montrouge,
Ile-de-France, 92120,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA DBV Common Stock Euronext Paris FR EUR 29. Mar 2012
OTCPK DBVT.F Common Stock Pink Sheets LLC US USD 29. Mar 2012
DB DBV Common Stock Deutsche Boerse AG DE EUR 29. Mar 2012
LSE 0QAJ Common Stock London Stock Exchange GB EUR 29. Mar 2012
BATS-CHIXE DBVP Common Stock BATS 'Chi-X Europe' GB EUR 29. Mar 2012
NasdaqGS DBVT SPON ADR EACH REPR ORD Nasdaq Global Select US USD 23. Oct 2014
DB DBVA SPON ADR EACH REPR ORD Deutsche Boerse AG DE EUR 23. Oct 2014
Number of employees
Current staff
Staff numbers
323
DBV Technologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 23:51
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/03/20
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.